linjc16/ctgov huggingface dataset:
Sensory Processing Difficulties in Adults and Adolescents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish normative data for the Adult/Adolescent Sensory History (ASH) and to determine if the ASH is able to discriminate between individuals aged 13-95 years, with Autism Spectrum Disorder (ASD) with or without co-morbid Sensory processing Disorder (SPD), individuals with SPD with no co-morbid ASD, and individuals who are typically functioning. It is anticipated that individuals with ASD will have the most problems with sensory processing, those with SPD will also have problems in comparison to typical individuals. It is also hypothesized that the measure will be able to discriminate between the three groups.

Official Title
-----------------
Standardization of the Adult/ Adolescent Sensory History

Conditions
-----------------
Sensory Processing Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Autism and Sensory Processing groups aged 18-95 years, Typical group aged 13-95 years Have no self-reported diagnosed neurological motor coordination problem (e.g. cerebral palsy) Have no mental health diagnoses involving psychosis (e.g. manic-depression or schizophrenia) Be able to read and speak sufficient English as survey is only available in English. Exclusion Criteria: Outside of the designated age range Unable to complete the survey independently

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Autism<br>Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder. | |
| Sensory Processing<br>Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder | |
| Typical<br>Typically functioning individuals aged 13-95 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensory processing difficulties | This study proposes to measure sensory processing problems by self report | 15-20 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sensory Processing, Autism
Individualized PEEP Setting by EIT in Patients With ARDS

Study Overview
=================
Brief Summary
-----------------
The investigators conducted a pilot study to compare the effect of Positive End Expiratory Pressure(PEEP) setting guide by lung electrical impedance tomography(EIT) and ARDS-net PEEP-FiO2 table on survival in subjects with mild/severe Acute Respiratory Distress Syndrome(ARDS).

Official Title
-----------------
Individualized Positive End Expiratory Pressure(PEEP) Setting by EIT in Patients With Acute Respiratory Distress Syndrome(ARDS)

Conditions
-----------------
the PEEP Setting of ARDS

Intervention / Treatment
-----------------
* Other: the EIT guide the individualized PEEP Setting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: acute respiratory distress syndrome with ratio of partial pressure of arterial oxygen over fraction of inspired oxygen (PaO2:FiO2)<300 and PEEP >5cmH2O Body mass index < =40 Written inform consent Exclusion: pregnant，intracranial hypertension left ventricular dysfunction (EF<25% ) Patients with end-stage conditions(death expected within 90 days)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EIT group<br>the Individualized PEEP titration by EIT was administered to the patients in the EIT group. | Other: the EIT guide the individualized PEEP Setting<br>* the EIT guide the individualized PEEP Setting in the EIT group<br>|
| No Intervention: control group<br>If patients are assigned to the control group, the Individualized PEEP Setting was by PEEP-FiO2 table based on ARDS-net protocol. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival | Non-survive and survive | 28-day | 
| Arterial oxygenation | PaO2(mmHg) measured by blood gas analysis | 72h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of ICU stay and mechanical ventilated day | Days of ICU stay and received mechanical ventilation(day) | 28days | 
| pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; | new-onset of pneumothorax and barotrauma | 7days |
Clinical Evaluation of a Progressive Addition Lens (PAL)

Study Overview
=================
Brief Summary
-----------------
The purpose of the trial is to clinically evaluate the performance of a progressive addition lens among presbyopic patients. This evaluation will be done by performing visual tests and collecting subjective information from subjects wearing the lens which will be manufactured according to personal prescription.

Official Title
-----------------
Clinical Performance Evaluation of a Progressive Addition Lens Among Presbyopic Patients

Conditions
-----------------
Presbyopia

Intervention / Treatment
-----------------
* Device: Progressive Addition Lens (Shamir PrimeIITM) Spectacles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: An ability to comprehend and give an informed consent for participation in the trial Presbyopia Exclusion Criteria: Concurrent participation in another clinical trial Age<18 For female subjects: pregnancy \ planning a pregnancy \ lactating at the time of enrollment Imbalanced diabetes \ high blood pressure \ thyroid disease Infectious disease Inability (cognitively) to comprehend the instructions given during the trial and to comply with them

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Horizontal Intermediate Visual Field |  | Baseline | 
| Visual Acuity |  | Baseline | 
| Horizontal Near Visual Field |  | Baseline | 
| Field of comfortable reading on a computer screen |  | Baseline | 
| Horizontal Far Visual Field |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective Evaluation of Visual Quality |  | 2-3 weeks | 
| Overall Subjective Feedback |  | 2-3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Progressive Addition Lens, Multifocal, Presbyopia
Effects of OMT on ANS: a Thermography Study

Study Overview
=================
Brief Summary
-----------------
the study will investigate the effect of a specific type of touch intervention on the activity of autonomic nervous system measured using thermography

Official Title
-----------------
Effects of Osteopathic Manipulative Treatment on Autonomic Nervous System: a Thermography Study

Conditions
-----------------
Autonomic Nervous System Imbalance, Healthy

Intervention / Treatment
-----------------
* Other: osteopathic treatment
* Other: sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults above 18y and below 35y without any congenital, genetical and chronic disease without any symptomatology Exclusion Criteria: congenital, genetical and chronic disease neurological, cardiovascular, psychiatric disease acute pain paediatric patients adults over 35 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: randomised placebo controlled crossover study
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: study<br>participants will receive a single touch intervention based on osteopathic assessment and treatment | Other: osteopathic treatment<br>* the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified<br>Other: sham<br>* the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique<br>|
| Sham Comparator: Control<br>participants will receive a single touch sham intervention mimicking the intervention | Other: osteopathic treatment<br>* the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified<br>Other: sham<br>* the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| temperature | variability of the autonomic nervous system measured by temperature variability of the face | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin conductance | pre-post changes of physiological parameter of electrodermal skin response | 1 week | 
| heart rate variability | pre-post changes of HRV | 1 week |
Influence of Non-steroidal Anti-inflammatory Drugs (NSAID) on Muscle Regeneration

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the influence of non-steroidal anti-inflammatory drugs (NSAIDs) on muscle regeneration. The investigators' hypothesis is that ingestion of NSAID will delay or impair muscle regeneration.

Detailed Description
-----------------
The model employed to induce muscle damage is electrical stimulation. Muscle biopsies will be examined to follow the response of satellite cells and muscle regeneration. Study participants will be randomly assigned to a placebo or NSAID group in a double-blinded manner.

Official Title
-----------------
The Influence of Blocking Inflammatory Activity in Vivo on Skeletal Muscle Regeneration in Humans

Conditions
-----------------
Muscle Damage

Intervention / Treatment
-----------------
* Drug: NSAID
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male healthy does not exercise regularly Exclusion Criteria: displays contraindications for taking NSAID well-trained

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NSAID<br>receive NSAID | Drug: NSAID<br>* Effect of NSAID ingestion on muscle regeneration<br>|
| Placebo Comparator: Placebo<br>receive placebo | Drug: placebo<br>* receive placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle regeneration |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Muscle regeneration, Satellite cells, electrical stimulation, eccentric contractions, myogenic precursor cells
Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to evaluate the acute effects of oxygen supplementation during a submaximal exercise test in patients with Eisenmenger's Syndrome.

Detailed Description
-----------------
Patients with Eisenmenger's syndrome were submitted to a submaximal exercise test (six-minute walking test) with and without supplemental oxygen. The distance walked during the two tests were compared to assess the impact of oxygen supplementation on the walking distance.

Official Title
-----------------
Acute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome

Conditions
-----------------
Eisenmenger Complex, Hypertension, Pulmonary

Intervention / Treatment
-----------------
* Other: Oxygen Supplementation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Abscence of heart failure and/or respiratory infection Advanced therapy for pulmonary hypertension Exclusion Criteria: Lung, liver or connective tissue diseases Neuromuscular diseases Inability to perform a pulmonary function test and/or chronic lung disease Inability to walk

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oxygen Supplementation<br>Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source. | Other: Oxygen Supplementation<br>* Oxygen delivery was continuous by mask at 40%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance walked during the six-minute walk tests | Distance walked during the six-minute walk tests with and without oxygen supplementation were recorded and compared to each other to establish the impact of the intervention. | At enrollment |
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

Official Title
-----------------
Treatment Efficacy for Drug Abuse and AIDS Prevention

Conditions
-----------------
Cocaine-Related Disorders, Heroin Dependence

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 26 Years
Maximum Age: 41 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors

Study Overview
=================
Brief Summary
-----------------
To report the patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital in the next 10 years, and collect the postoperative complications and limb function of these patients.

Detailed Description
-----------------
To report the patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital in the next 10 years. The basic data, treatment methods, postoperative complications and limb function of these patients were collected.

Official Title
-----------------
Application of 3D Printed Bone Prosthesis in Limb Salvage Surgery for Bone Tumors: a Single-center, Real-world Prospective Observational Study

Conditions
-----------------
Malignant Tumor

Intervention / Treatment
-----------------
* Other: 3D printed bone prosthesis replacement surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women of all ages are welcome. Pathologically confirmed in our hospital as a subtype of malignant tumor. He received 3D printed bone prosthesis replacement in our hospital. Exclusion Criteria: Not applicable.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 3D printed bone prosthesis replacement surgery<br>Patients undergoing 3D-printed bone prosthesis replacement surgery | Other: 3D printed bone prosthesis replacement surgery<br>* To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications | Complications were collected from patients who underwent 3D-printed bone prosthesis replacement surgery. | From surgery to 24 months after surgery | 
| Limb function | Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project. | Patients were enrolled until 24 months after surgery |
Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intrathecal Injection for SCI

Study Overview
=================
Brief Summary
-----------------
This trial will study the safety and efficacy of intrathecal injection of cultured autologous adult adipose derived mesenchymal stem cells for the treatment of spinal cord injury

Detailed Description
-----------------
Studies have shown that stem cell treatment is safe and efficacious for the treatment of spinal cord injury (SCI). This patient funded trial aims to study the safety and efficacy of intrathecal injection of cultured autologous adult adipose derived mesenchymal stem cells (AD-MSCs) for the treatment of SCI. Patients with SCI will receive a single intrathecal injection of AD-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Official Title
-----------------
Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Spinal Cord Injury

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Biological: autologous adipose derived mesenchymal stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Spinal Cord Injury Understanding and willingness to sign a written informed consent document Exclusion Criteria: Active infection Active cancer Chronic multisystem organ failure Pregnancy Anticoagulation medicine use Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety. Previous organ transplant Hypersensitivity to sulfur Continued drug abuse Pre-menopausal women not using contraception
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group<br>Single intrathecal injection of 100 million cells | Biological: autologous adipose derived mesenchymal stem cells<br>* cultured autologous adult adipose derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | Clinical monitoring of possible adverse events or complications | Four year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: American Spinal Injury Association Impairment Scale (ASIA) | It will be completed for each follow up point | Four year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
spinal cord injury, SCI, stem cell treatment